Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine-lidocaine for postoperative pain in gynecological laparoscopy
NCT04906889Withdrawn
- Sponsor
- The Catholic University of Korea
- Start
- Jun 2021
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of dexmedetomidine and Lidocaine Hydrochloride Injection, without epinephrine in acute postoperative pain (2 arms), sponsored by The Catholic University of Korea. Primary endpoint: Postoperative pain in recovery room at 30 months. Planned start Jun 2021; status: withdrawn.
02
Drugs
dexmedetomidineLidocaine Hydrochloride Injection, without epinephrine
03
Conditions
acute postoperative pain
Beyond the preview
Go deeper on NCT04906889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04906889.